hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-05 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
=== Development === On September 30, 2024, FX gave the project an 11-episode series order. The series is based on The Beauty, a creator-owned comic book written by Jeremy Haun and Jason A. Hurley and published by Image Comics. The original comic follows two detectives investigating a sexually transmitted disease that makes those infected physically beautiful but ultimately proves fatal due to side effects. Mac Quayle, a frequent collaborator with Murphy, composed the score for the series.
=== Deep Learning === More recently, deep learning techniques have been applied to solve the de novo peptide sequencing problem. The first breakthrough was DeepNovo, which adopted the convolutional neural network structure, achieved major improvements in sequence accuracy, and enabled complete protein sequence assembly without assisting databases Subsequently, additional network structures, such as PointNet (PointNovo), have been adopted to extract features from a raw spectrum. The de novo peptide sequencing problem is then framed as a sequence prediction problem. Given previously predicted partial peptide sequence, neural-network-based de novo peptide sequencing models will repeatedly generate the most probable next amino acid until the predicted peptide's mass matches the precursor mass. At inference time, search strategies such as beam search can be adopted to explore a larger search space while keeping the computational cost low. Comparing with previous methods, neural-network-based models have demonstrated significantly better accuracy and sensitivity. Moreover, with a careful model design, deep-learning-based de novo peptide sequencing algorithms can also be fast enough to achieve real-time peptide de novo sequencing. PEAKS software incorporates this neural network learning in their de novo sequencing algorithms.
=== Pharmacokinetics === Nadolol is classified as a beta blocker with low lipophilicity and hence lower potential for crossing the blood–brain barrier. This in turn may result in fewer effects in the central nervous system as well as fewer neuropsychiatric side effects.
Sources: en.wikipedia.org
At the time, these findings were seen as a confirmation of Franz Joseph Gall's theory that language was localized and that certain psychological functions were localized in specific areas of the cerebral cortex. The localization of function hypothesis was supported by observations of epileptic patients conducted by John Hughlings Jackson, who correctly inferred the organization of the motor cortex by watching the progression of seizures through the body. Carl Wernicke further developed the theory of the specialization of specific brain structures in language comprehension and production. In 1894, neurologist and psychiatrist Edward Flatau published a human brain atlas "Atlas of the Human Brain and the Course of the Nerve-Fibres" which consisted of long-exposure photographs of fresh brain sections. In 1897, Charles Scott Sherrington introduced the name "synapse" for the connection between neurons.
In Portal, the player controls the protagonist, Chell, from a first-person perspective as she navigates a series of test chambers using the Aperture Science Handheld Portal Device, commonly known as the portal gun, under the supervision of the artificial intelligence GLaDOS. The portal gun can create two distinct portal ends, blue and orange, which connect different locations within the test chambers. The portals form a connection between two points in three-dimensional space, allowing Chell and objects to pass between them. Neither portal functions exclusively as an entrance or exit, as objects entering one emerge from the other. The game's physics preserve an object's momentum as it passes through a portal, while its trajectory is determined by the orientation of the exit portal. A common maneuver involves placing one portal below the player, falling through it to gain speed, and emerging from another portal positioned on a wall or other surface. This technique allows the player to redirect momentum and launch Chell or objects across gaps and other obstacles. The technique is commonly referred to as "flinging". When portal surfaces are positioned at different orientations, the player's orientation changes when passing through them so that the character remains aligned with the game's gravitational direction. Chell and objects that fit through the portal openings can pass between them, while portals cannot be fired through an existing open portal. Portals cannot be placed on moving objects, glass, certain surfaces, liquids, or areas that are too small to accommodate them.
The Harry Benjamin International Gender Dysphoria Association (HBIGDA), now known as the World Professional Association for Transgender Health (WPATH), was formed in 1979, with the first version of the Standards of Care published the same year. The Endocrine Society published guidelines for the hormonal care of transgender people in 2009, with a revised version in 2017. Hormone therapy for transgender women was initially done using high-dose estrogen therapy with oral estrogens such as conjugated estrogens, ethinylestradiol, and diethylstilbestrol and with parenteral estrogens such as estradiol benzoate, estradiol valerate, estradiol cypionate, and estradiol undecylate. Progestogens, such as hydroxyprogesterone caproate, medroxyprogesterone acetate, and other progestins, were also sometimes included. The antiandrogen and progestogen cyproterone acetate was first used in transgender women by 1977. Its use was standard at the Center of Expertise on Gender Dysphoria (CEGD; Kennis- en Zorgcentrum Genderdysforie, or KZcG) in Amsterdam, the Netherlands by 1985. Spironolactone, another antiandrogen, was first used in transgender women by 1986. These agents were described as allowing the use of much lower doses of estrogen than previously required, and this was considered advantageous due to risks of high doses of estrogens such as cardiovascular complications. Antiandrogens were well-established in hormone therapy for transgender women by the early 1990s. Estrogen doses in transgender women were reduced following the introduction of antiandrogens.
Sources: en.wikipedia.org
ACE in plasma was discovered by Leonard T. Skeggs, Norman Shumway, and their colleagues in 1956, but at that time there was no known physiological basis for its use in heart failure treatment. That changed in 1962, when the physiological rationale for using vasodilators to reduce afterload in heart failure was established by American cardiologist Edmund Sonnenblick through force-velocity studies of isolated cardiac muscle. These studies demonstrated that the resistance against which the ventricle contracts directly determines its performance—providing the theoretical justification for afterload reduction as a therapeutic strategy that ACE inhibitors would later exploit. Around this time, it was also noted that those who worked in banana plantations in South-western Brazil collapsed after being bitten by a pit viper, leading to a search for a blood pressure lowering component in its venom. Brazilian scientist Sérgio Henrique Ferreira reported a bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca, a South American pit viper, in 1965. Ferreira then went to John Vane's laboratory as a postdoctoral fellow with his already-isolated BPF. The conversion of the inactive angiotensin I to the potent angiotensin II was thought to take place in the plasma. However, in 1967, Kevin K. F. Ng and John R. Vane showed plasma ACE is too slow to account for the conversion of angiotensin I to angiotensin II in vivo. Subsequent investigation showed rapid conversion occurs during its passage through the pulmonary circulation.
=== Freedom of expression === A devout advocate for democracy, Bhutto Zardari has repeatedly denounced censorship and likened any forms of curbing media freedom to living under a dictatorship. He made a speech at the Karachi Press Club on World Press Freedom Day where he said, "An undeclared censorship is stifling the freedom of expression in Pakistan and journalists are coming under threat from state and non-state actors." He added, "Journalists and media persons as human rights defenders suffer the most when freedom of expression is stifled. After the right to life, the most important right is the right of expression and the freedom of association because all other rights cannot even be articulated without it." During the speech, he also criticized the Prevention of Electronic Crime Act 2016 and stated that it had been misapplied to stifle dissent.
=== Dextran microsphere applications === Dextran-based microspheres can encapsulate a variety of drugs and provide therapeutic delivery in the treatment of diseases such as cancer, colonic diseases, bone diseases, and cardiovascular diseases.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.